mavrilimumab
KPL-301-C203
Phase 3 small_molecule completed
Quick answer
mavrilimumab for COVID is a Phase 3 program (small_molecule) at Kiniksa Pharmaceuticals International, plc with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Kiniksa Pharmaceuticals International, plc
- Indication
- COVID
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- completed